HiCLR is the first foundation model that can be broadly applied to various synthesis-related tasks, and it achieves state-of-the-art performance in reaction classification, reaction condition recommendation, reaction yield prediction, synthesis planning, and even molecular property prediction.
Jialu Wu, Yiheng Zhu, Xiaorui Wang et al.· JACS Au· 0 citations
RSGPT, a generative model pre-trained on ten billion data points, achieving state-of-the-art performance for synthesis planning, and introduces reinforcement learning to capture the relationships among products, reactants, and templates more accurately.
Yafeng Deng, Xinda Zhao, Hanyu Sun et al.· Nature Communications· 18 citations· ⚡2
AntiBMPNN consistently outperforms AbMPNN, AntiFold, and ProteinMPNN in designing complementarity determining regions (CDR) 1‐3, yielding stronger binding affinities and confirming its potential to improve therapeutic antibody design.
Ze-Yu Sun, Jiayi Yuan, Divya Jaiswal et al.· Advancement of science· 9 citations
The AI-guided development of a first-in-class proteolysis-targeting chimera (PROTAC) designed to selectively degrade the CLIP1-LTK fusion protein is reported, providing a promising therapeutic strategy for overcoming acquired resistance in kinase-driven cancers.
Shi-Cheng Chen, Hai-Ting Duan, S. Zhong et al.· Proceedings of the National...· 0 citations
ERAM aligns pre-trained molecular representations from Protein Language Model with the knowledge of enzyme catalysis by modeling enzymatic reactions as multi-relational data, and demonstrates its potential as a versatile and effective tool for enzyme catalysis research.
This study introduces LaMGen, an LLM-powered framework that leverages large-scale protein-ligand data and rotation-aware molecular encoding to rapidly produce chemically plausible multi-target candidates, achieving strong zero-shot generalization, superior molecular quality, and robust performance across dual- and trip...
Qun Su, Qiaolin Gou, Hui Zhang et al.· Nature Communications· 1 citation
The Biotoxins Database (BioTD) is the largest open-source database for toxins, offering open access to 14,607 data records (8,185 activity records), covering 8,975 toxins sourced from 5,220 references and patents across over 900 species.
Gaoang Wang, Hang Wu, Yang Liao et al.· Journal of Chemical Informat...· 0 citations
BBBP-Atlas is proposed, a structure-aware BBB permeability prediction model designed for unified modeling of small molecules and peptides with the first cross-modal dataset OmniBBBP, which offers a versatile and cross-modal approach for single-compound prediction, batch screening, and dataset exploration for CNS drug d...
Xin Shen, Qun Su, Hao Luo et al.· bioRxiv· 0 citations
An integrated computational workflow that combines enhanced sampling techniques and machine learning collective variables to identify druggable conformations of the AR-NTD and elucidate the binding mechanism of its modulator, EPI-002 is introduced.
Kai Zhu, Huating Wang, Jin-Tu Zhang et al.· Nature Communications· 0 citations
ProphDR is an interpretable deep learning framework that integrates multiomics data and drug structural information using a hierarchical attention mechanism, and generates biologically interpretable attention maps that highlight key pharmacophores and resistance-related genes consistent with established mechanisms in N...
Yundian Zeng, Qing Ye, Jike Wang et al.· Journal of Chemical Informat...· 0 citations
The first comprehensive benchmarking framework specifically designed to accommodate inter-dataset heterogeneity is presented, finding that well-designed small datasets can match or even surpass the performance of larger benchmarks, suggesting that different metrics are applicable to different datasets/testing scenarios...
Yingjuan Cheng, Qing Ye, Linlong Jiang et al.· Journal of Cheminformatics· 0 citations
A novel committor learning framework grounded in the AlphaFold 3 paradigm is proposed that elucidates how ligand substituents regulate the ratio between distinct binding pathways, offering new perspectives for structure-based drug design.
Jintu Zhang, Zichang Jin, Huifeng Zhao et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.